Modulation of aldosterone via adrenal gland stimulation

Patent metadata

Field	Value
Publication number	US-11147967-B2
Application number	US-201816163811-A
Country	US
Kind code	B2
Filing date	Oct 18, 2018
Priority date	Oct 18, 2017
Publication date	Oct 19, 2021
Grant date	Oct 19, 2021

Abstract

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a plurality of stimulation elements arranged configured to deliver stimulation energy through at least one of the plurality of stimulation elements to modulate aldosterone levels within the patient.

First claim

We claim:

1. An apparatus for delivering therapy to an adrenal gland of a patient, the apparatus comprising:
a housing sized and configured to attach between a capsule surrounding the adrenal gland and remaining portions of the adrenal gland;
a plurality of stimulation elements arranged with the housing configured to deliver stimulation energy through at least one of the plurality of stimulation elements to modulate production of aldosterone by the patient; and
a controller configured to instruct alteration of the stimulation energy on a duty cycle based on a metabolization time of aldosterone within the patient in response to feedback based on symptoms of the patient to maintain aldosterone levels within the patient to a calibrated target level or within normal basal levels of the patient.

2. The apparatus of claim 1 , wherein the plurality of stimulation elements are configured to stimulate the adrenal gland and inhibit or block the release of aldosterone by the patient.

3. The apparatus of claim 1 , wherein the housing is a leadless housing configured to engage the portion of the adrenal gland.

4. The apparatus of claim 1 , wherein the housing is a lead body configured to engage the portion of the adrenal gland.

5. The apparatus of claim 1 , wherein the plurality of stimulation elements are configured to deliver at least one of electrical stimulation, light stimulation, sound stimulation, thermal stimulation, and magnetic stimulation to the adrenal gland to modulate the aldosterone levels within the patient.

6. The apparatus of claim 1 , wherein the plurality of stimulation elements are configured to deliver stimulation to maintain the aldosterone levels within the patient within normal basal levels.

7. The apparatus of claim 1 , wherein the plurality of stimulation elements are configured to deliver stimulation energy at a frequency between 2 Hz and 20 kHz.

8. The apparatus of claim 1 , wherein the plurality of stimulation elements are configured to deliver stimulation energy to a cortex or outer layer of the adrenal gland of the patient.

9. The apparatus of claim 8 , wherein the delivery of stimulation energy modulates the renin-angiotensin-aldosterone system (RAAS) within the patient.

10. The apparatus of claim 9 , wherein the delivery of stimulation energy interrupts the renin-angiotensin-aldosterone system (RAAS) thereby lowering production of aldosterone by the patient.

11. The apparatus of claim 1 , wherein the delivery of stimulation energy lessens aldosterone plasma levels in the patient to treat at least one of heart failure, chronic kidney disease, and cardiorenal syndrome.

12. An apparatus for delivering therapy to an adrenal gland of a patient, the apparatus comprising:
a housing sized and configured to attach between a capsule surrounding the adrenal gland and remaining portions of the adrenal gland;
a plurality of stimulation elements arranged with the housing configured to deliver stimulation energy through at least one of the plurality of stimulation elements to modulate aldosterone levels within the patient;
a sensor configured to measure the aldosterone levels within the patient; and
a controller configured to instruct alteration of the stimulation energy on a duty cycle based on a metabolization time of aldosterone within the patient in response to feedback based on the aldosterone levels measured by the sensor to maintain the aldosterone levels within the patient to a calibrated target level or within normal basal levels of the patient.

13. The apparatus of claim 12 , wherein the sensor is configured to alter the stimulation energy delivered through the at least one of the plurality of stimulation elements to maintain the aldosterone levels within the patient within normal basal levels.

14. The apparatus of claim 12 , wherein the sensor is arranged with the housing.

15. The apparatus of claim 12 , wherein the housing comprises a communications component configured to communicate wireless signals, and the sensor is configured to measure the aldosterone levels within the patient and communicate feedback to the communication component via wireless signals to alter the stimulation energy delivered through the at least one of the plurality of stimulation elements to maintain the aldosterone levels within the patient within the normal basal levels of the patient.

16. The apparatus of claim 12 , wherein the sensor is at least one of a chemical sensor configured to sense chemical levels within the patient associated with the aldosterone levels, a blood pressure sensor configured to sense blood pressure levels associated with the aldosterone levels, a time of day sensor configured to sense blood pressure levels associated with the aldosterone levels, and a sleep status sensor configured to sense blood pressure levels associated with the aldosterone levels.

17. A method of delivering therapy to an adrenal gland of a patient, the method comprising:
delivering a housing sized and configured to implant between a portion of the adrenal gland of the patient and a capsule surrounding the adrenal gland, the housing including a plurality of stimulation elements arranged with the housing;
delivering stimulation energy through at least one of a plurality of electrodes leadless implantable medical energy on a duty cycle based on a metabolization time of aldosterone within the patient to modulate aldosterone levels within the patient; and
instructing alteration of the stimulation energy in response to feedback based on symptoms of the patient to maintain aldosterone levels within the patient to a calibrated target level or within normal basal levels of the patient.

18. The method of claim 17 , further comprising using a sensor to measure the aldosterone levels within the patient and altering the stimulation energy delivered through the at least one of the plurality of stimulation elements based on measured aldosterone levels.

Assignees

• Boston Scient Neuromodulation Corp

Inventors

• Swanson Lynne E
• Huibregtse Barbara
• Clark Bryan A
• Werner Dennis B
• Brill Natalie A
• Govea Michael X
• Anand Umang
• Stoffregen William C

Classifications

• A61N1/0507

  Electrodes for the digestive system · CPC title

• A61N1/36007 Primary

  of urogenital or gastrointestinal organs, e.g. for incontinence control · CPC title

• A61N1/3614

  based on impedance measurement · CPC title

• A61N1/3756

  Casings with electrodes thereon, e.g. leadless stimulators · CPC title

• A61N1/3606

  adapted for a particular treatment · CPC title